About: Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
Source	Medline; PMC
abstract	Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established in mice but not in rats. The authors used a target animal safety trial to evaluate the safety of extended-release buprenorphine in rats. Fischer 344 rats received post-surgical subcutaneous injections of 1.3 mg, 3.9 mg or 6.5 mg buprenorphine per kg body weight (two times, six times or ten times the intended dose, respectively), and their body weight, clinical signs and symptoms, clinical pathology and histopathology were monitored for 4 d. Body weight was not significantly different in rats that received buprenorphine compared with control rats. Signs of nausea-related behavior were observed in 25% of the rats treated with buprenorphine. Clinical pathology results for all rats were normal, and gross and microscopic histopathology examinations identified no substantial abnormalities, suggesting that this behavior was of minor consequence. Other adverse events previously reported to occur with opiate therapy, including weight loss and dermal lesions at drug injection sites, were not observed in this study. The results of this study show that post-surgical administration of an extended-release buprenorphine product is safe in Fischer 344 rats and does not necessarily cause substantial adverse effects, confirming that opiate therapy is a viable choice in laboratory animal medicine.
has issue date	2015-12-18(xsd:dateTime)
bibo:doi	10.1038/laban.745
bibo:pmid	26684956
has license	no-cc
sha1sum (hex)	d3b4cd3d7aa46f8795e95ed4734b69ae69870504
schema:url	https://doi.org/10.1038/laban.745
resource representing a document's title	Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
has PubMed Central identifier	PMC7092016
has PubMed identifier	26684956
schema:publication	Lab Anim (NY)
resource representing a document's body	covid:d3b4cd3d7aa46f8795e95ed4734b69ae69870504#body_text
is schema:about of	named entity 'buprenorphine' named entity 'buprenorphine' named entity 'experimental group' named entity 'therapeutic index' named entity 'buprenorphine' named entity 'Mycoplasma pulmonis' named entity 'opiate' named entity 'glycerol' named entity 'nausea' named entity 'hair loss' named entity 'weight loss' named entity 'body weight' named entity 'rat' named entity 'safety profile' named entity 'Torrington, CT' named entity 'human diseases' named entity 'body weight' named entity 'buprenorphine' named entity 'rat' named entity 'one-way analysis of variance' named entity 'nausea' named entity 'capillary refill time' named entity 'Nausea' named entity 'skin lesions' named entity 'West Caldwell' named entity 'body weight' named entity 'organ' named entity 'rat' named entity 'hematology' named entity 'buprenorphine' named entity 'extended-release' named entity 'buprenorphine' named entity 'hair loss' named entity 'pneumonia' named entity 'Torrington, CT' named entity 'buprenorphine' named entity 'extended-release' named entity 'TAS' named entity 'body weight' named entity 'protein' named entity 'muscle' named entity 'subcutaneous injection' named entity 'rodents' named entity 'US Food and Drug Administration' named entity 'Romeoville' named entity 'anesthetized' named entity 'pain management' named entity 'body weight' named entity 'R Foundation' named entity 'rat' named entity 'San Diego' named entity 'Sprague-Dawley rats' named entity 'anesthesia' named entity 'inflammation' named entity 'adverse effect' named entity 'Carlsbad, CA' named entity 'rat' named entity 'body weight' named entity 'buprenorphine' named entity 'rat' named entity 'body weight' named entity 'drug injection' named entity 'body weight' named entity 'laboratory animals' named entity 'US Food and Drug Administration' named entity 'buprenorphine' named entity 'subcutaneous injection' named entity 'drug injection' named entity 'analgesic' named entity 'long-acting' named entity 'buprenorphine' named entity 'assay' named entity 'buprenorphine' named entity 'Body weight' named entity 'surgical incision' named entity 'nausea' named entity 'nausea' named entity 'cholesterol' named entity 'reovirus' named entity 'polycarbonate' named entity 'weight loss' named entity 'nausea'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software